Throat Bracelet Helps Patients Suffering from Acid Reflux

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Monday, May 13, 2013
The LINX Reflux Management System, which was approved by the FDA in 2012, has demonstrated impressive results in a study involving 100 participants with long-term acid reflux.

Researchers have reported promising results of a study of a surgical device used to treat gastroesophageal reflux disease (GERD). The LINX Reflux Management System, which was approved by the FDA in March 2012, consists of a ring of titanium beads with magnets inside that is placed at the bottom of the esophagus through a surgical procedure.
The flexible ring expands when a patient swallows, but otherwise keeps the esophagus closed to prevent bile from regurgitating. At rest, the ring is approximately 0.5 inches in diameter, but it can expand up to 1.5 inches in diameter.
In a feasibility study conducted by the device’s manufacturer, 26 men and 18 women with an average age of 42 received the ring. Each patient in the study had suffered from acid reflux for at least 10 years and had not improved with medication. Once the ring was in place, the amount of acid in participants’ throats decreased significantly; within a year after surgery, 86% of participants did not need medication.
Now, the results of a larger study, also supported by the device’s manufacturer, have been published in the February 21, 2013, edition of the New England Journal of Medicine. The 100 participants in this study (52 men, 48 women, median age 53) had experienced acid reflux symptoms for a median of 10 years, ranging from 1 year to 40 years. Patients had a median treatment time with proton pump inhibitors of 5 years.
Of the 100 participants, 6 experienced adverse events, and 4 of those patients asked that the device be removed (3 due to dysphagia and 1 due to vomiting, which persisted after removal). Sixty-eight percent of patients experienced dysphagia after implementation, but at 1 year, only 11% still reported this problem. At 2 years, this number had fallen to 5% and at 3 years it was 4%.
The study’s authors noted that it is unclear whether the device could be easily removed more than 2.9 years after being placed in the body. (This is the latest point after placement at which a patient had the device removed). The authors noted, however, that patients reported no trouble with erosions or migrations in this study or in the pilot study. The medical community is continuing to monitor for erosion through existing registries and clinical use.
Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues